208 related articles for article (PubMed ID: 23445087)
1. Medical strategies to reduce amputation in patients with type 2 diabetes.
Malik RA; Tesfaye S; Ziegler D
Diabet Med; 2013 Aug; 30(8):893-900. PubMed ID: 23445087
[TBL] [Abstract][Full Text] [Related]
2. Reducing the incidence of foot ulceration and amputation in diabetes.
Bartus CL; Margolis DJ
Curr Diab Rep; 2004 Dec; 4(6):413-8. PubMed ID: 15539004
[TBL] [Abstract][Full Text] [Related]
3. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.
Rajamani K; Colman PG; Li LP; Best JD; Voysey M; D'Emden MC; Laakso M; Baker JR; Keech AC;
Lancet; 2009 May; 373(9677):1780-8. PubMed ID: 19465233
[TBL] [Abstract][Full Text] [Related]
4. A model to estimate cost-savings in diabetic foot ulcer prevention efforts.
Barshes NR; Saedi S; Wrobel J; Kougias P; Kundakcioglu OE; Armstrong DG
J Diabetes Complications; 2017 Apr; 31(4):700-707. PubMed ID: 28153676
[TBL] [Abstract][Full Text] [Related]
5. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study.
Mohammedi K; Woodward M; Hirakawa Y; Zoungas S; Colagiuri S; Hamet P; Harrap S; Poulter N; Matthews DR; Marre M; Chalmers J;
Cardiovasc Diabetol; 2016 Sep; 15(1):129. PubMed ID: 27590190
[TBL] [Abstract][Full Text] [Related]
6. Lowering the risk of neuropathy, foot ulcers and amputations.
Boulton AJ
Diabet Med; 1998; 15 Suppl 4():S57-9. PubMed ID: 9868994
[TBL] [Abstract][Full Text] [Related]
7. Amputations and foot ulcers in patients newly diagnosed with type 2 diabetes mellitus and observed for 19 years. The role of age, gender and co-morbidity.
Bruun C; Siersma V; Guassora AD; Holstein P; de Fine Olivarius N
Diabet Med; 2013 Aug; 30(8):964-72. PubMed ID: 23617411
[TBL] [Abstract][Full Text] [Related]
8. How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.
Steiner G
Cardiovasc Drugs Ther; 2009 Oct; 23(5):403-8. PubMed ID: 19757004
[TBL] [Abstract][Full Text] [Related]
9. Fibrates and microvascular complications in diabetes--insight from the FIELD study.
Ansquer JC; Foucher C; Aubonnet P; Le Malicot K
Curr Pharm Des; 2009; 15(5):537-52. PubMed ID: 19199980
[TBL] [Abstract][Full Text] [Related]
10. Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?
Athyros VG; Mitsiou EK; Tziomalos K; Karagiannis A; Mikhailidis DP
Curr Vasc Pharmacol; 2010 Jan; 8(1):1-4. PubMed ID: 20394107
[No Abstract] [Full Text] [Related]
11. Complexity of factors related to outcome of neuropathic and neuroischaemic/ischaemic diabetic foot ulcers: a cohort study.
Gershater MA; Löndahl M; Nyberg P; Larsson J; Thörne J; Eneroth M; Apelqvist J
Diabetologia; 2009 Mar; 52(3):398-407. PubMed ID: 19037626
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Neuropathy, Glycemic Control, and Revascularization as Risk Factors for Future Lower Extremity Amputation among Diabetic Patients.
Goldman MP; Corriere MA; Craven T; Davis RP; Sheehan M; Hurie JB; Velazquez G; Williams TK; Chang K; Edwards MS
Ann Vasc Surg; 2021 May; 73():254-263. PubMed ID: 33248240
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
Otsuki M; Goya K; Kasayama S
Vasc Health Risk Manag; 2005; 1(3):209-15. PubMed ID: 17319106
[TBL] [Abstract][Full Text] [Related]
14. Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium-glucose cotransporter-2 inhibitors versus other medications: A systematic review and meta-analysis of observational cohort studies.
Hodgson A; Gillies CL; Highton P; Haddon L; Gharibzadeh S; Zaccardi F; Khunti K
Diabetes Obes Metab; 2024 Jun; 26(6):2487-2491. PubMed ID: 38558251
[No Abstract] [Full Text] [Related]
15. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM
Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
[TBL] [Abstract][Full Text] [Related]
16. [Diabetic neuropathy: new therapeutic options?].
Haslbeck M
MMW Fortschr Med; 2006 Nov; 148(44):41-4. PubMed ID: 17619441
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; Neal B; Patel A; Woodward M; Chalmers J; ; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F
Diabetes Care; 2009 Nov; 32(11):2068-74. PubMed ID: 19651921
[TBL] [Abstract][Full Text] [Related]
18. The effects of improved glycemic control on complications in type 2 diabetes.
Gaster B; Hirsch IB
Arch Intern Med; 1998 Jan; 158(2):134-40. PubMed ID: 9448551
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes.
Hicks CW; Selvin E
Curr Diab Rep; 2019 Aug; 19(10):86. PubMed ID: 31456118
[TBL] [Abstract][Full Text] [Related]
20. Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus. A randomized, controlled trial.
Litzelman DK; Slemenda CW; Langefeld CD; Hays LM; Welch MA; Bild DE; Ford ES; Vinicor F
Ann Intern Med; 1993 Jul; 119(1):36-41. PubMed ID: 8498761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
